Testing the ability of oral nicotinamide riboside to replenish heart tissue levels of oxidized nicotinamide adenine dinucleotide using heart biopsies taken at the time of surgery.

Determining Feasibility of Human Myocardial NAD+ Replenishment using Oral Nicotinamide Riboside Supplementation in Adults with Diastolic Dysfunction – The CardioNAD Study

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12622000340730

Enrollment

Registered

2022-02-24

Start date

2022-04-05

Completion date

2024-04-02

Last updated

2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We recently discovered deficiency of a molecule called oxidized nicotinamide adenine dinucleotide in hearts from patients with stiff heart failure. In a mouse model of stiff heart failure, we then demonstrated that replenishing this molecule using the stable precursor nicotinamide riboside could completely rescue this disease. Now, we would like to test in this study if oral administration of nicotinamide riboside can sufficiently replenish this molecule in patients hearts using samples of their heart tissue taken at the time of cardiothoracic surgery.

Interventions

Determining if oral supplementation of the NAD+ precursor nicotinamide riboside (NR) at a dose of 1g twice per day is sufficient to replenish left ventricular myocardial NAD+ levels and to improve mitochondrial respiration. Supplement Details: Generic name: Nicotinamide riboside (NR). Supplier: Chromadex. Dose administered: 1g twice/day of NR. Duration of administration: one month. Mode of administration: oral capsule. Compliance strategies: drug tablet return, verbal confirmation

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. All participants who have equal to or greater than Grade 2 diastolic dysfunction 2. Male and female 3. Adults equal to or greater than 18 years of age 4. Concomitant diseases: all patients eligible regardless of concomitant disease. Except for end-stage renal disease (CKD equal to or greater than 4) or end-stage liver disease or malignant cancer. 5. Willingness to provide informed consent and willingness to participate. 6. Agreement of the treating cardiothoracic surgeon.

Exclusion criteria

1. Participants with end-stage kidney (CKD equal to or greater than 4) or liver failure (hepatic encephalopathy with impaired synthetic function as determined by INR equal to or greater than 1.5 in the absence of anticoagulant therapy). 2. Participants with a history of a psychological illness or other conditions which may interfere with their ability to understand the study requirements. 3. Patients already taking NAD+ precursors including niacin, nicotinamide, or nicotinamide riboside

Outcome results